Research

Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial 

This 2021 open label active-controlled clinical trial followed osteoarthritic patients for 6 weeks. The intervention group received low-dose curcumagalactomannosides (CGM) (400 mg once daily) in OA subjects. The treatment was compared with a standard combination of 500 mg glucosamine hydrochloride (GLN) and 415 mg chondroitin sulphate (CHN), supplied as a single oral dose twice a day. CGM exhibited  improvement in VAS, KPS and walking performance, respectively, compared to the baseline. 

References:

Thomas JV, Smina TP, Khanna A, Kunnumakkara AB, Maliakel B, Mohanan R, Krishnakumar IM. Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial. Phytother Res. 2021 Mar;35(3):1443-1455. doi: 10.1002/ptr.6907. Epub 2020 Nov 18. PMID: 33210408. 

Ingredient in this research

Let’s keep in touch

Don’t worry we only send updates monthly on offers, product changes, and new opportunities for you.

Due to increased order volumes, some orders may experience shipping delays. Thank you for your patience and understanding.
×
Why Choose to Subscribe and Save?
  • Automatically re-order your favorite products on your schedule.
  • Easily change the products or shipping date for your upcoming Scheduled Orders.
  • If you decide a subscription is not for you, it can be cancelled after 2 renewals.